Skip to main content
SpringerLink
Log in

Adjuvant Therapy of Breast Cancer

  • Book
  • © 1992

Overview

Editors:
  1. I. Craig Henderson

    1. University of California, San Francisco, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Cancer Treatment and Research (CTAR, volume 60)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (17 chapters)

  1. Front Matter

    Pages i-ix
    Download chapter PDF

  2. Rationale and Methods for Studying Adjuvant Systemic Therapy

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. Evolving concepts in the adjuvant systemic therapy of operable breast cancer

      • Larry Norton
      Pages 3-25

    3. Statistical methods for early breast cancer trials

      • Rebecca Gelman
      Pages 27-53

  3. Results of Clinical Studies

    1. Front Matter

      Pages 55-55
      Download chapter PDF

    2. The nature of the benefit

      • I. Craig Henderson
      Pages 57-68

    3. Adjuvant endocrine therapy of breast cancer

      • Maureen E. Trudeau, Kathleen I. Pritchard
      Pages 69-114

    4. Adjuvant chemotherapy of axillary lymph-node-positive breast cancer

      • Nancy E. Davidson, Martin D. Abeloff
      Pages 115-145

    5. The node-negative problem

      • David L. Ahmann
      Pages 147-158

  4. Special Problems

    1. Front Matter

      Pages 159-159
      Download chapter PDF

    2. Defining the high-risk breast cancer patient

      • Gary M. Clark, William L. McGuire
      Pages 161-187

    3. Models for weighing benefits and toxicities

      • Richard D. Gelber, Aron Goldhirsch
      Pages 189-206

    4. Financial considerations in the use of adjuvant chemotherapy

      • Rebecca Johnson Irvin, John G. Kuhn
      Pages 207-222

    5. The use of adjuvant therapy in patients treated with conservative surgery and radiotherapy

      • Abram Recht, Daniel F. Hayes, Jay R. Harris
      Pages 223-237

    6. Treating the relapsed patient

      • Rowan T. Chlebowski
      Pages 239-253

  5. Future Directions

    1. Front Matter

      Pages 255-255
      Download chapter PDF

    2. Unanswered questions in the adjuvant therapy of breast cancer

      • F. Andrew Dorr, Michael A. Friedman
      Pages 257-278

    3. Neoadjuvant chemotherapy

      • William C. Wood
      Pages 279-291

    4. Altering cell kinetics with endocrine therapy

      • R. Paridaens
      Pages 293-313

    5. Polypeptide growth factors: their potential value in the management of breast cancer patients

      • C. Kent Osborne
      Pages 315-329
Back to top

Keywords

About this book

The results of randomized trials evaluating the use of early or adjuvant systemic treatment for patients with resectable breast cancer provide an eloquent rebuttal to those who would argue that we have made no progress in the treatment of cancer. Many of the tumors that we have been most successful in curing with chemotherapy and other newer forms of treatment are relatively uncommon. In contrast, breast cancer continues to be the single most common malignancy among women in the western world, is increasingly a cause of death throughout Asia and Third-World countries, and remains one of the most substantial causes of cancer mortality world­ wide. The use of mammography as a means of early detection has been shown to reduce breast cancer mortality by 25-35% among those popu­ lations in which it is utilized. The use of adjuvant systemic treatment in appropriate patients provides a similar (and additional) reduction in breast cancer mortality. Few subjects have been so systematically studied in the history of medicine, and it seems fair to conclude that the value to adjuvant systemic therapy in prolonging the lives of women with breast cancer is more firmly supported by empirical evidence than even the more conventional or primary treatments using various combinations ofsurgery and radiotherapy.

Reviews

'Overall, this book is a useful review Volume containing thoughtful and up-to-date information on the optimal use of adjuvant therapy for breast cancer. It will be a valuable addition to the library of the practicing clinical oncologist.' Journal of the Nat. Cancer Inst. 85:10 1993

Editors and Affiliations

  • University of California, San Francisco, USA

    I. Craig Henderson

Bibliographic Information

  • Book Title: Adjuvant Therapy of Breast Cancer

  • Editors: I. Craig Henderson

  • Series Title: Cancer Treatment and Research

  • DOI: https://doi.org/10.1007/978-1-4615-3496-9

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 1992

  • Hardcover ISBN: 978-0-7923-1656-5Published: 31 August 1992

  • Softcover ISBN: 978-1-4613-6550-1Published: 05 November 2012

  • eBook ISBN: 978-1-4615-3496-9Published: 06 December 2012

  • Series ISSN: 0927-3042

  • Series E-ISSN: 2509-8497

  • Edition Number: 1

  • Number of Pages: XVI, 464

  • Topics: Oncology

Publish with us

Policies and ethics

Back to top

Search

Navigation